Treating IPF—all or nothing? A PRO‐CON debate Journal Articles

abstract

• ABSTRACTThe Idiopathic Pulmonary Fibrosis (IPF) is a progressive fibrotic lung disease with poor prognosis. It is distinct from other idiopathic interstitial pneumonias by its histopathological pattern of usual interstitial pneumonia which is characterized by accumulation of fibroblasts, extracellular matrix and honeycombing. Inflammation is only scarce in true IPF. The use of anti‐inflammatory therapy is still part of guidelines for IPF management, although not specifically recommended, because convincing evidence showing beneficial effects of this approach is lacking. This review provides a summary of important arguments PRO and CON using anti‐inflammatory and anti‐oxidant therapy for patients with IPF in form of a debate with a concluding statement of both positions at the end.

authors

• BEHR, Jürgen
• Kolb, Martin Rainer
• Cox, Gerard

status

• published 

publication date

• November 2009

has subject area

• 11 Medical and Health Sciences (FoR)
• Anti-Inflammatory Agents (MeSH)
• Antioxidants (MeSH)
• Fibroblasts (MeSH)
• Humans (MeSH)
• Idiopathic Pulmonary Fibrosis (MeSH)
• Immunosuppressive Agents (MeSH)
• Lung (MeSH)
• Respiratory System (Science Metrix)

published in

• Respirology  Journal

keywords

• Anti-Inflammatory Agents
• Antioxidants
• Fibroblasts
• Humans
• Idiopathic Pulmonary Fibrosis
• Immunosuppressive Agents
• Lung

Digital Object Identifier (DOI)

• 10.1111/j.1440-1843.2009.01645.x

PubMed ID

• 19909457

start page

• 1072

end page

• 1081

volume

• 14

issue

• 8